Skip to main content
SpringerLink
Log in

Malignes neuroleptisches Syndrom

  • Conference paper
Katatone und dyskinetische Syndrome

Zusammenfassung

Jean Delay und Pierre Deniker beschreiben 1968 im Handbook of Clinical Neurology unter der Überschrift „Drug-induced extrapyramidal syndromes“ [39] erstmals einen Symptomkomplex von hohem Fieber, verbunden mit ei nem extrem ausgeprägten Rigor sowie Stupor als seltene, potentiell letale Komplikation einer neuroleptischen Behandlung: das maligne neuroleptische Syndrom (MNS).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Allan RN, White HC (1984) Side effects of parenteral long-acting phenothiazines. Br Med J I: 221

    Google Scholar 

  2. Arznei-Telegramm (1984) 8:66-67

    Google Scholar 

  3. Aubert C (1973) Les hyperthermies dues aux neuroleptiques. Encéphale 62:126–159

    PubMed  CAS  Google Scholar 

  4. Auzépy P, Poivet D, Nitenberg G (1977) Insuffisance respiratoire aigue chez deux schizophrenes. Role éventuel des neuroleptiques retard. Nouv Presse Méd 6:1236

    Google Scholar 

  5. Ayd FJ (1956) Fatal hyperpyrexia during chlorpromazine therapy. J Clin Exp Psychopathol 17:189–192

    PubMed  Google Scholar 

  6. Bates I, Courtenay-Evans RJ (1984) Neuroleptic malignant syndrome. Br Med J 288:1913

    Article  CAS  Google Scholar 

  7. Bengzon A, Hippius, H, Kanig K (1966) Some changes in the serum during treatment with psychotropic drugs. J Nerv Dis 143:369–376

    Article  CAS  Google Scholar 

  8. Benoit P, Melandri P, Dupont D, Grimaud DD, Maestracci (1981) Le syndrome malin des neuroleptiques. Conc Med 103:1063–1080

    Google Scholar 

  9. Berman MC, Harrison GG, Bull AB et al. (1970) Changes underlying halothane-in duced malignant hyperpyrexia in Landrace pigs. Nature 225:653–655

    Article  PubMed  CAS  Google Scholar 

  10. Bernstein RA (1979) Malignant neuroleptic syndrome: An atypical case. Psychosomatics 20:840–846

    PubMed  CAS  Google Scholar 

  11. Bhugra D (1984) Neuroleptic malignant syndrome. Br J Psychiatry 145:449

    PubMed  CAS  Google Scholar 

  12. Birkheimer LJ, De Vane CL (1984) The neuroleptic malignant syndrome: Presentation and treatment. Drug Intell Clin Pharm 18:462–465

    Google Scholar 

  13. Bismuth C, Elkharat D (1982) Theoretical indication of dantrolene in neuroleptic malig nant syndrome. Efficacy in three cases. Vet Hum Toxicol (Suppl) 52–55

    Google Scholar 

  14. Bismuth C, de Rohan-Chabot P, Goulon M, Raphael JC (1984) Dantrolene -A new therapeutic approach to the neuroleptic malignant syndrome. Acta Neurol Scand 70 (Suppl) 100:193–198

    Google Scholar 

  15. Boles JM, Lecam B, Mialon P, Pennec Y, Garre M (1982) Hyperthermie maligne des neuroleptiques. Guerison rapide par le dantrolene. Nouv Presse Med 11:674

    PubMed  CAS  Google Scholar 

  16. Bond WS (1984) Detection and management of the neuroleptic malignant syndrome. Clin Pharm 3:302–307

    PubMed  CAS  Google Scholar 

  17. Bourgeois M, Tignol J, Henry P (1971) Syndromes malins et morts subites au cours des traitements par neuroleptiques simples et retard. Ann Med Psychol (Paris) 2:729–746

    CAS  Google Scholar 

  18. Bourgeois M, Tignol J, Villeger M, Henry P, Daubech J-F, Laforge E, Durand J (1981) Le syndrome malin des neuroleptiques. Réévaluation a propos de 2 cas. Ann Med Psychol (Paris) 2:547–556

    Google Scholar 

  19. Brenner I, Rheuban WJ ( 1978) The catatonic dilemma. Am J Psychiatry 135:1242–1243

    PubMed  CAS  Google Scholar 

  20. Britt BA, Kalow W (1970) Malignant hyperthermia: A statistical review. Can Anaesth Soc J 17:293–315

    Article  PubMed  CAS  Google Scholar 

  21. Britt BA (1979) Etiology and pathophysiology of malignant hyperthermia. Fed Proc 38:44–48

    PubMed  CAS  Google Scholar 

  22. Britt BA (1982) Malignant hyperthermia: A review. In: Handbook of experimental pharmacology, Vol 60: Pyretics and antipyretics, pp 547–615

    Google Scholar 

  23. Burke RE, Fahn S, Mageux R, Weinberg H, Louis K, Willner JH (1981) Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 31:1022–1026

    PubMed  CAS  Google Scholar 

  24. Cameron AE, Borthwick JM (1983) Neuroleptic malignant syndrome. Br Med J 287:128–129

    Google Scholar 

  25. Caroff SN (1980) The neuroleptic malignant syndrome. J Clin Psychiatry 41:79–83

    PubMed  CAS  Google Scholar 

  26. Caroff SN, Rosenberg H, Gerber JC (1983) Neuroleptic malignant syndrome and malignant hyperthermia. Lancet 1:244

    Article  PubMed  CAS  Google Scholar 

  27. Caroff SN, Rosenberg H, Gerber JC (1983) Neuroleptic malignant syndrome and malignant hyperthermia. J Clin Psychopharmacol 3:120–121

    Article  PubMed  CAS  Google Scholar 

  28. Caroff SN (1984) Persönliche Mitteilung

    Google Scholar 

  29. Chayasirisobhon S, Cullis P, Veeramasuneni RR (1983) Occurrence of neuroleptic malignant syndrome in a narcoleptic patient. Hosp Community Psychiatry 34:548–550

    PubMed  CAS  Google Scholar 

  30. Clark WG, Lipton JM, (1984) Drug -related heatstroke. Pharmacol Ther 26:345–388

    Article  PubMed  CAS  Google Scholar 

  31. Clough CG (1983) Neuroleptic malignant syndrome. Br Med J 287:128–129

    Google Scholar 

  32. Cohen WJ Cohen NH (1974) Lithium carbonate, haloperidol and irreversible brain damage. JAMA 230:1283–1287

    Article  PubMed  CAS  Google Scholar 

  33. Coons DJ, Hillman FJ, Marshall RW (1982) Treatment of neuroleptic syndrome with dantrolene sodium. A case report. Am J Psychiatry 139:944–945

    PubMed  CAS  Google Scholar 

  34. Coons DJ (1983) Questions about dantrolene for neuroleptic malignant Syndrome. Am J Psychiatry 140:137–139

    Google Scholar 

  35. Cope RV, Gregg EM (1983) Neuroleptic malignant syndrome. Br Med J 286:1938

    Article  CAS  Google Scholar 

  36. Cordt A, Schlegel U, Jerusalem F (1986) Malignes Dopa-Entzugs-Syndrom (MDES).Aktuel Neurol 1399–102

    Article  Google Scholar 

  37. Cruz FG, Thiagarajan D, Harney JH (1983) Neuroleptic malignant syndrome after haloperidol therapy. South Med J 76:684–686

    Article  PubMed  CAS  Google Scholar 

  38. D’Arcy PF, Griffin JP (1979) Iatrogenic diseases. Oxford University Press, New York pp 281–294

    Google Scholar 

  39. Deal RW, Shah C, Diamond BI, Borison RI (1984) Neuroleptic malignant syndrome. Neurology 34 (Suppl) 1:211

    Google Scholar 

  40. Deboscker Y, Laurent JM, Lemaire V, Dequiedt P, Tacquet A (1982) Insuffisance renale aigue par rhabdomyolyse non traumatique. Nouv Presse Med 11:131

    PubMed  CAS  Google Scholar 

  41. Delacour JL, Daoudal P, Chapoutot JL, Rocq B (1981) Traitement du syndrome malin des neuroleptiques par le dantrolene. Nouv Presse Med 10:3572–2573

    PubMed  CAS  Google Scholar 

  42. Delay J, Pichot P, LemperiereT, Elissalde B, Peigne F (1960) Un neuroleptique majeur non phenothiazine et non reserpinique L’haloperidol dans le traitement des psychoses. Ann Med Psychol (Paris) 118:145–152

    Google Scholar 

  43. Delay J, Deniker P (1968) Drug-induced extrapyramidal syndroms. In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, diseases of the basal ganglia, Vol 6. Elsevier, Amsterdam, pp 248–266

    Google Scholar 

  44. Denborough MA, Lovell RRH (1962) Anaesthetic deaths in a family. Br J Anaesth 34:395–396

    Article  PubMed  CAS  Google Scholar 

  45. Denborough MA, Dennett X, Anderson RMD (1973) Central-core disease and malig nant hyperpyrexia. Br Med J 1:272–273

    Article  PubMed  CAS  Google Scholar 

  46. Denborough MA, Collins SP, Hopkinson KC (1984) Rhabdomyolysis and malignant hyperpyrexia. Br Med J 288:1878

    Article  CAS  Google Scholar 

  47. Destee A, Montagne B, Rousseaux M, Petit H, Warot P (1980) Incidents et accidents des neuroeptiques (110 hospitalisations en neurologie) Lille Med 25:291–295

    PubMed  CAS  Google Scholar 

  48. Dhib-Jalbut S, Hesseibrock R, Brott T, Silbergeld D (1983) Treatment of the neuroleptic malignant syndrome with bromocriptine. JAMA 250:484–485

    Article  PubMed  CAS  Google Scholar 

  49. Dillon JB (1972) Parenteral long-acting phenothiazines. Br Med J 1:807

    Article  PubMed  CAS  Google Scholar 

  50. Downey GP, Rosenberg M, Caroff S et al. (1984) Neuroleptic malignant syndrome. Patient with unique clinical and physiology. Features Am J Med 77:338–341

    CAS  Google Scholar 

  51. Duke M (1984) Neuroleptic malignant syndrome. Med J Aust 141:198–199

    PubMed  CAS  Google Scholar 

  52. Dumont A, Minjat M, Blanc JL, Vignon H (1978) Le syndrome malin aux neuroleptiques. A propos de trois observations. Ann Anesth Franc 19:777–782

    CAS  Google Scholar 

  53. Durocher A, Chopin C, Gosselin B, Wattel F (1980) Rhabdomyolyses toxiques et médicamenteuses. Rev Med Interne 1:223–226

    Article  PubMed  CAS  Google Scholar 

  54. Eiser AR, Neff MS, Slifkin RF (1982) Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med 142:601–603

    Article  PubMed  CAS  Google Scholar 

  55. Eies GR, Songer JE, DiPette DJ (1984) Neuroleptic malignant syndrome complicated by disseminated intravascular coagulation. Arch Intern Med 44 144:1296–1297

    Google Scholar 

  56. Ellis FR, Cain PA, Harriman DGF (1978) Multifactorial inheritance of malignant hyperthermia susceptibility. In: Aldrete JA, Britt BA (eds) Second International Symposium on Malignant Hyperthermia. Grune & Stratton, New York, pp 329–338

    Google Scholar 

  57. Ellis KO, Carpenter JF (1972) Studies on the mechanism of action of dantrolene sodium, a skeletal muscle relaxant. Naunyn Schmiedebergs Arch Pharmacol 275:83–92

    Article  PubMed  CAS  Google Scholar 

  58. Fabre S, Gervais C, Manuel C, Vic-Dupont V (1977) Le syndrome malin des neuroleptiques: A propos de 7 cas. Encephale 3:321–326

    PubMed  CAS  Google Scholar 

  59. Feibel JH, Schiffer RB (1981) Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome: A case report. Am J Psychiatry 138:1115–1116

    PubMed  CAS  Google Scholar 

  60. Frank JP, Harati Y, Butler IJ, Nelson TE, Scott CI (1980) Central core disease and malignant hyperthermia syndrome. Ann Neurol 7:11–17

    Article  PubMed  CAS  Google Scholar 

  61. Gabris G, Müller C (1983) La catatonie dite „pernicieuse“. Encephale 9:365–385

    PubMed  CAS  Google Scholar 

  62. Gaertner HJ, Hörner W, Bartels M (1983) Katatonieforme Symptome als Nebenwirkung neuroleptischer Behandlung. Nervenarzt 54:250–254

    PubMed  CAS  Google Scholar 

  63. Geller B, Greydanus DE (1979) Haloperidol -Induced comatose state with hyperthermia and rigidity in adolescence: Two case reports with a literature review. J Clin Psychiatry 40:102–103

    PubMed  CAS  Google Scholar 

  64. Goekoop JG, Carbaat PAT (1982) Treatment of neuroleptic malignant syndrome with dantrolene. Lancet 11:49–50

    Article  Google Scholar 

  65. Goulon M, Rohan-Chabot P, Elkharrat D, Gajdos P, Bismuth C, Conse F (1983) Bene ficial effects of dantrolene in the treatment of neuroleptic malignant syndrome: A report of two cases. Neurology (Cleveland) 33:516–518

    CAS  Google Scholar 

  66. Granato JE, Stern BJ, Ringel A, Karim AH, Krumholz A, Coyle J, Adler S (1983) Neuroleptic malignant syndrome: Successful treatment with dantrolene and bromocriptine. Ann Neurol 14:89–90

    Article  PubMed  CAS  Google Scholar 

  67. Grant R (1984) Neuroleptic malignant syndrome. Br Med J 288:1690

    Article  Google Scholar 

  68. Gronert GA, Milde JH, Theye RA (1977) Role of sympathetic activity in porcine malignant hyperthermia. Anesthesiology 47:411–415

    Article  PubMed  CAS  Google Scholar 

  69. Gronert GA, Heffron JJA, Milde JH et al. (1977) Porcine malignant hyperpyrexia: Role of skeletal muscle in increased oxygen consumption. Can Anaesth Soc J 24:103–109

    Article  PubMed  CAS  Google Scholar 

  70. Gronert GA (1980) Malignant hyperthermia. Anesthesiology 53:395–423

    Article  PubMed  CAS  Google Scholar 

  71. Grunhaus L, Sancovici S, Rimon R (1979) Neuroleptic malignant syndrome due to depot fluphenazine. J Clin Psychiatry 40:99–100

    PubMed  CAS  Google Scholar 

  72. Guérin JM (1982) Syndrome malin des neuroleptiques. Med Interne 17:365–368

    Google Scholar 

  73. Gullotta F, Wierich W, Dieckmann J (1976) Maligne Hyperthermie, chronischer Alkoholismus und tubuläre Aggregate. Prakt Anästh 11:410–415

    CAS  Google Scholar 

  74. Gullotta F, Spieß-Kiefer C (1983) Muskelbioptische Untersuchungen bei maligner Hyperthermie. Anästh Intensivther Notfallmed 18:21–27

    Article  PubMed  CAS  Google Scholar 

  75. Gullotta F, Spieß-Kiefer C (1983) Idiopathische paroxysmale Rhabdomyolyse und klinisch latente Myopathie. Fortschr Neurol Psychiat 51:355–358

    Article  PubMed  CAS  Google Scholar 

  76. Haberman ML (1978) Malignant hyperthermia. An allergic reaction to thioridazine therapy. Arch Intern Med 138:800–801

    Article  PubMed  CAS  Google Scholar 

  77. Hackl JM, Engl J, Hofstädter F, Bonelli S, Rumpl E, Dworzak E, Puschendorf B (1981) Fragliche maligne Hyperthermie -Krise bei Medikamentenintoxikation. Wien Klin Wochenschr 93:475–479

    PubMed  CAS  Google Scholar 

  78. Häfner H, Kasper S (1982) Akute lebensbedrohliche Katatonie. Nervenarzt 53:385–394

    PubMed  Google Scholar 

  79. Harriman DGF, Ellis FR, Franks AJ, Sumner DW (1978) Malignant hyperthermia myopathie in man: An investigation of 75 families. In: Aldrete JA, Britt BA (eds) Second International Symposium on Malignant Hyperthermia. Grune & Stratton, New York, pp 67–87

    Google Scholar 

  80. Harriman DGF (1979) Preanesthetic investigation of malignant hyperthermia: Microscopy. Anesth Clin 17:97–117

    Article  CAS  Google Scholar 

  81. Harrison GG, Saunders SJ, Biebuyck JFet al. (1969) Anaesthetic -induced malignant hyperpyrexia and a method for its prediction. Br J Anaesth 41:844–855

    Article  PubMed  CAS  Google Scholar 

  82. Harrison GG (1975) Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. Br J Anaesth 47:62–65

    Article  PubMed  CAS  Google Scholar 

  83. Hashimoto F, Sherman CB, Jeffery WH (1984) Neuroleptic malignant syndrome and dopaminergic blockade. Arch Intern Med 144:629–630

    Article  PubMed  CAS  Google Scholar 

  84. Helpap B, Gullotta F, Schulteam Esch J (1983) Maligne Hyperthermie. In: Intensivmedizin, Notfallmedizin, Anaesthesiologie, Bd. 42.Thieme, Stuttgart

    Google Scholar 

  85. Henderson VW, Wooten GF (1981) Neuroleptic malignant syndrome: A pathogenetic role for dopamine receptor blockade? Neurology (NY) 31:132–137

    CAS  Google Scholar 

  86. Henry P, Barat M, Bourgeois M, Tignol P (1971) Syndrome malin mortel succédant a une injection d’emblée d’oénanthate de fluphenazine. Presse Med 79:1350

    PubMed  CAS  Google Scholar 

  87. Hilpert F, Cohen A, Auzepy P (1984) Le syndrome malin des neuroleptiques. Neuroleptiques 34:633–639

    CAS  Google Scholar 

  88. Hirsch J-F, Ohayon H, Pichard S (1982) Le syndrome malin des neuroleptiques. Gaz Med France 89:3711–3718

    Google Scholar 

  89. Imaeda M, Sakai M, Misugi N, Fujiwara T (1981) „Syndrome malin“ due to neuroleptics -Clinical and muscle studies of three cases. Yokohama Med Bull 32:57–69

    Google Scholar 

  90. Ingraham MR ,loo CJ, Tovin K (1982) The neuroleptic malignant syndrome: A case report. Int J Psychiat Med 12:43–47

    Article  CAS  Google Scholar 

  91. Isaacs H, Barlow MB (1970) Malignant hyperpyrexia during anaesthesia: Possible as sociation with subclinical myopathy. Br Med J 1:275–277

    Article  PubMed  CAS  Google Scholar 

  92. Isaacs H, Frere G, Mitchell J (1973) Histological, histochemical and ultramicroscopic findings in muscle biopsies from carriers of the trait for malignant hyperpyrexia. Br J Anaesth 45:860–868

    Article  PubMed  CAS  Google Scholar 

  93. Isaacs H, Barlow MB (1973) Malignant hyperpyrexia -Further muscle studies in asymptomatic carriers identified by creatinine phosphokinase screening. J Neurol Neurosurg Psychiatry 36:228–243

    Article  PubMed  CAS  Google Scholar 

  94. Itoh H, Ohtsuka N, Ogita K, Yagi G, Miura S, Koga Y (1977) Malignant neuroleptic syndrome -Its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn 31:565–576

    Google Scholar 

  95. Jerusalem F (1979) Muskelerkrankungen. Thieme, Stuttgart

    Google Scholar 

  96. Jessee SS, Anderson GF (1983) ECT in the neuroleptic malignant syndrome: Case report. J Clin Psychiatry 44:186–188

    PubMed  CAS  Google Scholar 

  97. Kalow W, Britt BA, Peter P (1978) Rapid simplified techniques for measuring caffeine contraction for patients with malignant hyperthermia. In: Aldrete JA, Britt BA (eds) Second International Symposium on Malignant Hyperthermia. Grune & Stratton, New York pp 339–351

    Google Scholar 

  98. Kammerer T, Singer L, Patris M, Finance F, Tempe J-D, Rey G (1972) Syndrome neuroleptique malin au surdosage neuroleptique (pipothiazine) -A propos d’une observation. Ann Med Psychol (Paris) 2:550–554

    CAS  Google Scholar 

  99. Kikuchi H, Morio M, Shinozaki M, Ishihara S (1978) Statistical considerations of malignant hyperthermia in Japan. In: Aldrete JA, Britt BA (eds) Second International Symposium on Malignant Hyperthermia. Grune & Stratton ,New York ,pp 483–499

    Google Scholar 

  100. Kimsey LR ,Gibbs JT ,Glen RS ,Markette JR ,Kosted E (1983) The neuroleptic malignant syndrome. Texas Med 79:54–55

    CAS  Google Scholar 

  101. King JO ,Denborough MA ,Zapf PW (1972) Inheritance of malignant hyperpyrexia. Lancet 1:365–370

    Article  PubMed  CAS  Google Scholar 

  102. Kleinknecht D ,Parent A ,Blot P ,Bochereau G ,Lallement PY ,Pourriat JL (1982) Rhabdomyolyses avec insuffisance renale aigue et syndrome malin des neuroleptiques. Ann Med Interne 133:549–552

    CAS  Google Scholar 

  103. Knezevic W ,Mastaglia FL ,Lefroy RB ,Fisher A (1984) Neuroleptic malignant syndrome. Med J Aust 140:28–30

    PubMed  CAS  Google Scholar 

  104. Kobayashi Y ,Suso K ,Suganuma Y ,Yamashita K (1983) Two cases of malignant syndrome in the field of psychiatry in which dantrolene sodium (i. v.) was effective. Abstracts , 7th Malignant Hypertemperature Study Assembly ,Osaka ,Japan

    Google Scholar 

  105. Konikoff F et al. (1984) Neuroleptic malignant syndrome induced by a single injection of haloperidol. Br Med J 289:1228

    Article  CAS  Google Scholar 

  106. Kümmerle HP ,Garrett ER ,Spitzy KH (1978) Klinische Pharmakologie und Phar-makotherapie ,3. Aufl. Urban & Schwarzenberg ,München

    Google Scholar 

  107. Langer G ,Heimann H (1983) Psychopharmaka. Grundlagen und Therapie. Springer ,Berlin Heidelberg New York Tokyo

    Google Scholar 

  108. Lazarus A (1985) Neuroleptic malignant syndrome and amantadine withdrawal. Am J Psychiatry 142:142

    PubMed  CAS  Google Scholar 

  109. Lazarus A (1986) Therapy of neuroleptic malignant syndrome. Psychiatr Develop 4 (l):19–30

    CAS  Google Scholar 

  110. Lenard HG ,Kettler D (1975) Malignant hyperpyrexia and myopathy. Neuropädiatrie 6:7–12

    Article  Google Scholar 

  111. Levenson JL (1985) Neuroleptic malignant syndrome. Am J Psychiatry 142:1137–1145

    PubMed  CAS  Google Scholar 

  112. Lew TY ,Tollefson G (1983) Chlorpromazine -Induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry 18:1441–1446

    PubMed  CAS  Google Scholar 

  113. Lievre JA ,Guillien P ,Boccara M (1971) Accident par fluphenazine -retard. Presse Med 79:1757

    PubMed  CAS  Google Scholar 

  114. Lister D ,Hall GM ,Lucke JN (1975) Malignant hyperthermia: A human and porcine stress syndrome. Lancet 1:519

    Article  PubMed  CAS  Google Scholar 

  115. Lotstra F, Linkowski P, Mendlewicz J (1983) General anesthesia after neuroleptic malignant syndrome. Biol Psychiatry 18:243–247

    PubMed  CAS  Google Scholar 

  116. Martin RD (1981) Mutism ,akinesis and fever -A review. Arizona Med 38:268–270

    PubMed  CAS  Google Scholar 

  117. May DC, Morris SW, Stewart RM, Fenton BJ, Gaffney FA (1983) Neuroleptic malig nant syndrome: Response to dantrolene sodium. Ann Intern Med 98:183–184

    PubMed  CAS  Google Scholar 

  118. Mc Allister RG (1978) Fever, tachycardia and hypertension with acute catatonic schizophrenia. Arch Intern Med 183:1154–1156

    Article  Google Scholar 

  119. McCarron MM, Boettger ML, Peck JJ (1982) A case of neuroleptic malignant syndrome successfully treated with amantadine. J Clin Psychiatry 43:381–382

    PubMed  CAS  Google Scholar 

  120. Melica AM, Belodi L, Negri F, Sacchetti E (1976) Serum creatine kinase in acute psychosis. Br J Psychiatry 129:191

    Article  PubMed  CAS  Google Scholar 

  121. Meltzer HY (1969) Muscle enzyme release in the acute psychoses. Arch Gen Psychiatry 21:102–112

    Article  PubMed  CAS  Google Scholar 

  122. Meltzer HY(1973) Rigidity ,hyperpyrexia and coma following fluphenazine enanthate. Psychopharmacologia 29:337–346

    Article  PubMed  CAS  Google Scholar 

  123. Meltzer HY, Ross-Stanton J, Schlessinger S (1980) Mean serum creatine kinase activity in patients with functional psychoses. Arch Gen Psychiatry 37:650–655

    Article  PubMed  CAS  Google Scholar 

  124. Mialon P, Boles JM, Abgrall JF, Garre M (1982) Malignant hyperthermia due to neuroleptic treatment. Quick recovery with dantrolene sodium therapy. Intensive Care Med 8 (5):249

    Google Scholar 

  125. Modestin J (1971) Die Beeinflussung der Körpertemperatur durch Neuroleptika. Schweiz Arch Neurol Neurochir Psychiatr 108:159–167

    PubMed  CAS  Google Scholar 

  126. Morris HH, McCormick WF, Reinarz JA (1980) Neuroleptic malignant syndrome. Arch Neurol 37:462–463

    Article  PubMed  Google Scholar 

  127. MortierW, Biesel C (1982) Pharmacological in-vitro studies in malignant hyperthermia in childhood. Brain Dev 4:347–352

    PubMed  CAS  Google Scholar 

  128. Moyes DG (1973) Malignant hyperpyrexia caused by trimeprazine. Br J Anaesth 45:1163–1164

    Article  PubMed  CAS  Google Scholar 

  129. Mueller PS, Vester JW, Fermaglich J (1983) Neuroleptic malignant syndrome. Successful treatment with bromocriptine. JAMA 249:386–388

    Article  PubMed  CAS  Google Scholar 

  130. Naganuma H, Toho M, Fujii K, Oda S, Honda Y, Honda N (1983) One case of neuroleptic malignant syndrome -Case of dantrolene effectiveness. Abstracts, 7th Malignant Hypertemperature Study Assembly, Osaka, Japan

    Google Scholar 

  131. Neseman ME, Michels JT, Pollei SR (1984) Neuroleptic malignant syndrome. Wisconsin Med J 83:12–14

    Google Scholar 

  132. Parini M, Archambeaud-Mouveroux F, Vincent D, Papapietro P, Dallet A (1984) Association d’une crise aigue thyrotoxique et d’un syndrome malin des neuroleptiques. Presse Med 13:1902

    PubMed  CAS  Google Scholar 

  133. Pearlman CA (1986) Neuroleptic malignant syndrome: A review of the literature. J Clin Psychopharmacol 6:257–273

    Article  PubMed  CAS  Google Scholar 

  134. Peele R, Loetzen IS von (1973) Phenothiazine deaths: A critical review. Am J Psychiatry 130:306–309

    PubMed  CAS  Google Scholar 

  135. Pera J, Decoux M, Guyon M, Sage M (1982) Reflexions sur le syndrome malin des neuroleptiques. Nouv Presse Med 11:2230

    PubMed  CAS  Google Scholar 

  136. Pirovino M, Meier J, Meyer M, Waldmeier P, Schmid M (1984) Malignes Neuroleptika-Syndrom. Dtsch Med Wochenschr 109:378–381

    Article  PubMed  CAS  Google Scholar 

  137. Powers P, DouglasTS,Waziri R (1976) Hyperpyrexia In catatonic states. Dis Nerv Syst 37:359–361

    PubMed  CAS  Google Scholar 

  138. Preston J (1959) CNS reactions to small doses of tranquilizers. Am Pract DigTreatm 10:627–630

    CAS  Google Scholar 

  139. Regestein QR, Alpert JS, Reich P (1977) Sudden catatonic stupor with disastrous outcome. JAMA 238:618–620

    Article  PubMed  CAS  Google Scholar 

  140. Reske-Nelsen E, Haase J, Kelstrup J (1975) Malignant hyperthermia in a family. Acta Path Microbiol Scand 83:651–660

    Google Scholar 

  141. Rosenberg H, Reed S (1983) In vitro contracture tests for susceptibility to malignant hyperthermia. Anesth Analg 62:415–420

    Article  PubMed  CAS  Google Scholar 

  142. Rosse R, Ciolino C (1985) Dopamine agonists and neuroleptic malignant syndrome. Am J Psychiatry 142:270–271

    PubMed  CAS  Google Scholar 

  143. Rowland PL, Willner J, Cerri C, di Mauro S, Miranda A (1980) Approaches to the membrane theory of Duchenne muscular dystrophy. In: Angelini C, Danieli GA, Fontanari D (eds) Muscular dystrophy research. Excerpta Medica, Amsterdam, pp 3–14

    Google Scholar 

  144. Samii K, Bagnat E, Glaser P, Nollet D, Simoni G (1976) Syndrome malin des neuroleptiques avec anurie d’évolution favorable. Nouv Presse Med 5:1538

    PubMed  CAS  Google Scholar 

  145. Sass H (1981) Probleme der Katatonieforschung. Nervenarzt 52:373–382

    PubMed  CAS  Google Scholar 

  146. Scarlett JD, Zimmermann R, Berkovic SF (1983) Neuroleptic malignant syndrome. Aust NZ J Med 13:70–73

    Article  CAS  Google Scholar 

  147. Schneider H, Krahn J (1978) Maligne Hyperthermie -Ein kasuistischer Beitrag einer möglicherweise nicht narkosebedingten Form der malignen Hyperthermie. Prakt Anä sth 13:59–62

    CAS  Google Scholar 

  148. Schrader G, Wong C, Russell R, Goldney RD (1981) The neuroleptic malignant syn drome. Med J Aust 2:494

    PubMed  CAS  Google Scholar 

  149. Schulte-Sasse U, Eberlein HJ (1983) Die maligne Hyperthermie. Anaesthesist 32:141–157

    PubMed  CAS  Google Scholar 

  150. Scott J (1984) Dantrolene for neuroleptic malignant syndrome. Br J Psychiatry 143:98

    Article  Google Scholar 

  151. Sechi GP, Tanda F, Mutani R (1984) Fatal hyperpyrexia after withdrawal of levodopa. Neurology (Cleveland) 34:249–251

    CAS  Google Scholar 

  152. Sechi GP, Becciu S, Demontis G, Rosati G (1984) Neuroleptic malignant syndrome in Parkinson’s disease. Book of Abstracts, Collegium Internationale Neuro -Psychophar macologicum 1 4th Congress, Florence, p 603

    Google Scholar 

  153. Shaler A, Aizenberg D, Munitz H (1984) The aftercare of the patient with the neuroleptic malignant syndrome. Biol Psychiatry 19:317–318

    Google Scholar 

  154. Shibuya K, Ohta H, Ikeda H (1984) Treatment of neuroleptic malignant syndrome with dantrolene sodium. Proc. Seventh Jap. Symposium on Malignant Hyperthermia. Hiroshima J Anesth 20 (Suppl):9–14

    Google Scholar 

  155. Simpson DM, Davis GC (1984) Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatry 141:796–797

    PubMed  CAS  Google Scholar 

  156. Singh G (1981) The malignant neuroleptic syndrome (A review with report of three cases) Indian J Psychiatry 23:179–183

    PubMed  CAS  Google Scholar 

  157. Singh T (1984) Neuroleptic malignant syndrome. Br J Psychiatry 144:98

    Article  Google Scholar 

  158. Skjoto J, Reikvam A (1979) Hyperthermia and rhabdomyolysis in self-poisoning with paracetamol and salicylates. Acta Med Scand 205:473–476

    Article  PubMed  CAS  Google Scholar 

  159. Smith JA, Carter JH (1984) Neuroleptic malignant syndrome with a positive Weil-Felix Test. Am J Psychiatry 141:609

    PubMed  Google Scholar 

  160. Solomons CC, Masson NC (1982) A platelet -Halothane bioassay for malignant hyperthermia. Anesthesiology 57:A 225

    Article  Google Scholar 

  161. Solomons CC, Masson NC (1984) Platelet model for halothane -Induced effects on nucleotide metabolism applied to malignant hyperthermia. Acta Anaesthesiol Scand 28:185–190

    Article  PubMed  CAS  Google Scholar 

  162. Soni SD (1976) Serum creatine phosphokinase in acute psychosis. Br J Psychiatry 128:181–183

    Article  PubMed  CAS  Google Scholar 

  163. Spieß-Kiefer C (1982) Morphologische und pathogenetische Betrachtungen über die maligne Hyperthermie. Inaugural-Dissertation, Bonn

    Google Scholar 

  164. Spieß-Kiefer C, Hippius H (1986) Malignes neuroleptisches Syndrom und maligne Hyperthermie -ein Vergleich. Fortschr Neurol Psychiatry 54:158–170

    Article  Google Scholar 

  165. Sporn P, Steinbreithner K, Sluga E, Linsmayer H, Schenk E (1980) Tödliche maligne Hyperthermiekrise in der Prämedikationsphase -„Humanes Streßsyndrom“ oder Promethazin als Triggeragens? Anaesthesist 29:85–88

    PubMed  CAS  Google Scholar 

  166. Spring G, Frankel M (1981) New data on lithium and haloperidol incompatibility. Am J Psychiatry 138:818–821

    PubMed  CAS  Google Scholar 

  167. Stanley B, Pal NR (1964) Fatal hyperpyrexia with phenelzine and imipramine. Br Med J II:1011

    Article  Google Scholar 

  168. Steers AJW, Tallack JA, Thompson DEA (1970) Fulminating hyperpyrexia during anaesthesia in a member of a myopathic family. Br Med J 11:341–343

    Article  Google Scholar 

  169. Sybesma W, Eikelenboom G (1969) Malignant hyperthermia syndrome in pigs. Neth J Vet Sci 2:155–160

    Google Scholar 

  170. Terwellen M (1978) Die paroxysmale Myoglobinurie. Inaugural-Dissertation, Bonn

    Google Scholar 

  171. Tollefson G (1982) A case of neuroleptic malignant syndrome: In vitro muscle comparism with malignant hyperthermia. J Clin Psychopharmacol 2:266–270

    PubMed  CAS  Google Scholar 

  172. Toru M, Matsuda O, Makiguchi K, Sugano K (1981) Neuroleptic malignant syndrome -Like state following a withdrawal of Antiparkinsonian drugs. J Nerv Ment Dis 169:324–327

    Article  PubMed  CAS  Google Scholar 

  173. Ungvari G, Pethö B (1979) Reversal of neuroleptic -Induced stupor by procyclidin. Pharmacopsychiatria 12:257–260

    Article  CAS  Google Scholar 

  174. Vinken PJ, Bruyn GW, Ringel SP (1979) Clinical presentations: Enzyme elevation (CPK). In: Vinken PJ, Bruyn GW (eds) Handbook of clinical neurology, Vol 40: Dis eases of the muscle. Elsevier, Amsterdam, pp 340–348

    Google Scholar 

  175. Wang RT, Aftergood DE, Carlson HE (1985) Hypercalcemia in the neuroleptic malignant syndrome. Arch Intern Med 145:143–144

    Article  PubMed  CAS  Google Scholar 

  176. Wedzicha JA, Hoffbrand BJ (1984) Neuroleptic malignant syndrome and hyponatriaemia. Lancet 1:963

    Article  PubMed  CAS  Google Scholar 

  177. Weinberger DR, Kelly MJ (1977) Catatonia and malignant syndrome: A possible complication of neuroleptic administration. J Nerv Ment Dis 165:263–268

    Article  PubMed  CAS  Google Scholar 

  178. White PD (1984) Treatment of neuroleptic malignant syndrome. Br J Psychiatry 144:437

    Article  PubMed  CAS  Google Scholar 

  179. Wingard DW (1974) Malignant hyperthermia: A human stress syndrome? Lancet II:1450–1451

    Article  Google Scholar 

  180. Yasukawa M, Jasukawa K, Hatakeyama Y, Chiba S, Suzuki T, Takami T (1983) A case study of neuroleptic malignant syndrome with myoglobinuria. Jpn J Anesthesiol 32:876–882

    CAS  Google Scholar 

  181. Zubenko G, Harrison GP (1983) Management of a case of neuroleptic malignant syndrome with bromocriptine. Am J Psychiatry 140:1619–1620

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Spiess-Kiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrischen Klinik und Poliklinik der Universität München, Nußbaumstraße 7, D-8000, München 2, Deutschland

    Hanns Hippius (Direktor der Psychiatrischen Klinik und Poliklinik der Universität München) (Direktor der Psychiatrischen Klinik und Poliklinik der Universität München)

  2. Psychiatrischen Klinik der Universität Göttingen, v.-Siebold-Straße 5, D-3400, Göttingen, Deutschland

    Eckart Rüther (Direktor der Psychiatrischen Klinik der Universität Göttingen) (Direktor der Psychiatrischen Klinik der Universität Göttingen)

  3. Psychiatrische Klinik und Poliklinik der Universität München, Nußbaumstraße 7, D-8000, München 2, Deutschland

    Max Schmauss (Oberarzt) (Oberarzt)

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Spiess-Kiefer, C. (1989). Malignes neuroleptisches Syndrom. In: Hippius, H., Rüther, E., Schmauss, M. (eds) Katatone und dyskinetische Syndrome. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83654-1_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-83654-1_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50501-3

  • Online ISBN: 978-3-642-83654-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation